What does this research mean for the field?

Progress in developing new therapies for axial spondyloarthritis is hindered by biological complexity and a reliance on treatments targeting downstream inflammation, necessitating the development of more pathophysiologically relevant preclinical models. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Assess preclinical models and emerging therapeutic targets to overcome current limitations in treating axial spondyloarthritis.

August 22, 2026Expert Opinion on Therapeutic Targets

Assessing the preclinical progress in the therapeutic targeting of axial spondyloarthritis

View Full Paper

Ask AI

Bookmark

Authors

RSRonan Soudy MJM. Jacoutot PGPaul Gervaise

Discussion

Member takes

Overview

Narrative review evaluates preclinical models and emerging therapeutic targets in axial spondyloarthritis, highlighting the need for improved disease models to advance targeted therapies.

Key Points

Assess preclinical models and emerging therapeutic targets to overcome current limitations in treating axial spondyloarthritis.
Reviewed preclinical models used to discover and validate therapeutic targets in axial spondyloarthritis.
Evaluated the capacity of existing models to mimic disease complexity and early biological mechanisms.
Therapeutic development remains slow because available treatments primarily target downstream inflammation rather than initial disease triggers.
Current preclinical systems fail to fully recapitulate human disease pathology, necessitating interdisciplinary approaches and models informed by related inflammatory diseases.

Cite This Study

Soudy et al. (2026) studied this question.

synapsesocial.com/papers/6a895ec3ca7ade938187ce56 https://doi.org/10.1080/14728222.2026.2722195

View Full Paper

Ask AI

Bookmark

August 22, 2026Expert Opinion on Therapeutic Targets

Assessing the preclinical progress in the therapeutic targeting of axial spondyloarthritis

View Full Paper

Ask AI

Bookmark

Authors

RSRonan Soudy MJM. Jacoutot PGPaul Gervaise

Discussion

Member takes

Overview

Narrative review evaluates preclinical models and emerging therapeutic targets in axial spondyloarthritis, highlighting the need for improved disease models to advance targeted therapies.

Key Points

Assess preclinical models and emerging therapeutic targets to overcome current limitations in treating axial spondyloarthritis.
Reviewed preclinical models used to discover and validate therapeutic targets in axial spondyloarthritis.
Evaluated the capacity of existing models to mimic disease complexity and early biological mechanisms.
Therapeutic development remains slow because available treatments primarily target downstream inflammation rather than initial disease triggers.
Current preclinical systems fail to fully recapitulate human disease pathology, necessitating interdisciplinary approaches and models informed by related inflammatory diseases.

Cite This Study

Soudy et al. (2026) studied this question.

synapsesocial.com/papers/6a895ec3ca7ade938187ce56 https://doi.org/10.1080/14728222.2026.2722195

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark